317 related articles for article (PubMed ID: 25797137)
1. Design of a PDZbody, a bivalent binder of the E6 protein from human papillomavirus.
Karlsson OA; Ramirez J; Öberg D; Malmqvist T; Engström Å; Friberg M; Chi CN; Widersten M; Travé G; Nilsson MT; Jemth P
Sci Rep; 2015 Mar; 5():9382. PubMed ID: 25797137
[TBL] [Abstract][Full Text] [Related]
2. Solution structure of the hDlg/SAP97 PDZ2 domain and its mechanism of interaction with HPV-18 papillomavirus E6 protein.
Liu Y; Henry GD; Hegde RS; Baleja JD
Biochemistry; 2007 Sep; 46(38):10864-74. PubMed ID: 17713926
[TBL] [Abstract][Full Text] [Related]
3. Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein.
Zhang Y; Dasgupta J; Ma RZ; Banks L; Thomas M; Chen XS
J Virol; 2007 Apr; 81(7):3618-26. PubMed ID: 17267502
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand.
Ramirez J; Poirson J; Foltz C; Chebaro Y; Schrapp M; Meyer A; Bonetta A; Forster A; Jacob Y; Masson M; Deryckère F; Travé G
Angew Chem Int Ed Engl; 2015 Jun; 54(27):7958-62. PubMed ID: 26014966
[TBL] [Abstract][Full Text] [Related]
5. Human Papillomavirus E6 interaction with cellular PDZ domain proteins modulates YAP nuclear localization.
Webb Strickland S; Brimer N; Lyons C; Vande Pol SB
Virology; 2018 Mar; 516():127-138. PubMed ID: 29346075
[TBL] [Abstract][Full Text] [Related]
6. Human Papillomavirus 16 (HPV-16), HPV-18, and HPV-31 E6 Override the Normal Phosphoregulation of E6AP Enzymatic Activity.
Thatte J; Banks L
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835500
[TBL] [Abstract][Full Text] [Related]
7. PDZ Domain-Containing Protein NHERF-2 Is a Novel Target of Human Papillomavirus 16 (HPV-16) and HPV-18.
Saidu NEB; Filić V; Thomas M; Sarabia-Vega V; Đukić A; Miljković F; Banks L; Tomaić V
J Virol; 2019 Dec; 94(1):. PubMed ID: 31597772
[TBL] [Abstract][Full Text] [Related]
8. PDZ domains and viral infection: versatile potentials of HPV-PDZ interactions in relation to malignancy.
Nagasaka K; Kawana K; Osuga Y; Fujii T
Biomed Res Int; 2013; 2013():369712. PubMed ID: 24093094
[TBL] [Abstract][Full Text] [Related]
9. Stabilization of HPV16 E6 protein by PDZ proteins, and potential implications for genome maintenance.
Nicolaides L; Davy C; Raj K; Kranjec C; Banks L; Doorbar J
Virology; 2011 Jun; 414(2):137-45. PubMed ID: 21489588
[TBL] [Abstract][Full Text] [Related]
10. Structural insights into a wildtype domain of the oncoprotein E6 and its interaction with a PDZ domain.
Mischo A; Ohlenschläger O; Hortschansky P; Ramachandran R; Görlach M
PLoS One; 2013; 8(4):e62584. PubMed ID: 23638119
[TBL] [Abstract][Full Text] [Related]
11. Biophysical characterization of the complex between human papillomavirus E6 protein and synapse-associated protein 97.
Chi CN; Bach A; Engström Å; Strømgaard K; Lundström P; Ferguson N; Jemth P
J Biol Chem; 2011 Feb; 286(5):3597-606. PubMed ID: 21113079
[TBL] [Abstract][Full Text] [Related]
12. Acquisition of a phospho-acceptor site enhances HPV E6 PDZ-binding motif functional promiscuity.
Sarabia-Vega V; Banks L
J Gen Virol; 2020 Sep; 101(9):954-962. PubMed ID: 30810519
[TBL] [Abstract][Full Text] [Related]
13. Surface plasmon resonance analysis of the binding of high-risk mucosal HPV E6 oncoproteins to the PDZ1 domain of the tight junction protein MAGI-1.
Fournane S; Charbonnier S; Chapelle A; Kieffer B; Orfanoudakis G; Travé G; Masson M; Nominé Y
J Mol Recognit; 2011; 24(4):511-23. PubMed ID: 20842623
[TBL] [Abstract][Full Text] [Related]
14. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
[TBL] [Abstract][Full Text] [Related]
15. High-risk HPV E6 oncoproteins assemble into large oligomers that allow localization of endogenous species in prototypic HPV-transformed cell lines.
García-Alai MM; Dantur KI; Smal C; Pietrasanta L; de Prat-Gay G
Biochemistry; 2007 Jan; 46(2):341-9. PubMed ID: 17209544
[TBL] [Abstract][Full Text] [Related]
16. Mapping the interactome of HPV E6 and E7 oncoproteins with the ubiquitin-proteasome system.
Poirson J; Biquand E; Straub ML; Cassonnet P; Nominé Y; Jones L; van der Werf S; Travé G; Zanier K; Jacob Y; Demeret C; Masson M
FEBS J; 2017 Oct; 284(19):3171-3201. PubMed ID: 28786561
[TBL] [Abstract][Full Text] [Related]
17. E6AP-dependent degradation of DLG4/PSD95 by high-risk human papillomavirus type 18 E6 protein.
Handa K; Yugawa T; Narisawa-Saito M; Ohno S; Fujita M; Kiyono T
J Virol; 2007 Feb; 81(3):1379-89. PubMed ID: 17121805
[TBL] [Abstract][Full Text] [Related]
18. Degradation of tyrosine phosphatase PTPN3 (PTPH1) by association with oncogenic human papillomavirus E6 proteins.
Jing M; Bohl J; Brimer N; Kinter M; Vande Pol SB
J Virol; 2007 Mar; 81(5):2231-9. PubMed ID: 17166906
[TBL] [Abstract][Full Text] [Related]
19. Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.
Conrady MC; Suarez I; Gogl G; Frecot DI; Bonhoure A; Kostmann C; Cousido-Siah A; Mitschler A; Lim J; Masson M; Iftner T; Stubenrauch F; Travé G; Simon C
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115863
[TBL] [Abstract][Full Text] [Related]
20. The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.
Zanier K; Stutz C; Kintscher S; Reinz E; Sehr P; Bulkescher J; Hoppe-Seyler K; Travé G; Hoppe-Seyler F
PLoS One; 2014; 9(11):e112514. PubMed ID: 25383876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
